Sacituzumab tirumotecan versus docetaxel for previously treated <i>EGFR</i>-mutated advanced non-small cell lung cancer: multicentre, open label, randomised controlled trial.

10 11 However, randomised phase 3 trials of sacituzumab govitecan and datopotamab deruxtecan in biomarker unselected patients with previously treated, advanced NSCLC (regardless of actionable genomic alterations) did not reach statistical significance for overall survival improvement. 12 13 To date, the US Food and Drug Administration has not approved any trophoblast cell surface antigen 2 directed antibody-drug conjugate for NSCLC.

also in 111,027 other papers